Prothena Shareholders Reaffirm Board, Auditor and Pay Policies

Prothena ( (PRTA) ) has issued an update.

On May 14, 2026, Prothena shareholders re-elected directors Shane M. Cooke and Dennis J. Selkoe to the board to serve until no later than the 2029 annual general meeting, affirming the company’s existing leadership structure and governance continuity. At the same meeting, investors ratified KPMG LLP as independent auditor for fiscal 2026, authorized the board’s audit committee to set the firm’s remuneration, and gave advisory approval to the compensation of Prothena’s named executive officers, signaling broad shareholder support for current financial oversight and executive pay practices.

The most recent analyst rating on (PRTA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.

Spark’s Take on PRTA Stock

According to Spark, TipRanks’ AI Analyst, PRTA is a Neutral.

The score is held back primarily by weak financial performance (persistent losses, negative cash flow, volatile milestone-driven revenue). Offsetting factors include a strong low-debt balance sheet and constructive earnings-call updates on partnered pipeline progress and cash runway, while technicals are modestly supportive and valuation looks optically cheap but reflects elevated biotech/event risk.

To see Spark’s full report on PRTA stock, click here.

More about Prothena

Prothena Corporation plc is a biotechnology company focused on discovering, developing, and commercializing therapies for neurodegenerative and other diseases. The company operates in the biopharmaceutical sector, targeting unmet medical needs with a pipeline of innovative protein-targeting drug candidates for global markets.

Average Trading Volume: 505,229

Technical Sentiment Signal: Strong Sell

Current Market Cap: $516.2M

See more data about PRTA stock on TipRanks’ Stock Analysis page.